Claro Advisors LLC Sells 139 Shares of Cencora, Inc. $COR

Claro Advisors LLC reduced its stake in Cencora, Inc. (NYSE:COR) by 11.6% during the 2nd quarter, Holdings Channel.com reports. The firm owned 1,058 shares of the company’s stock after selling 139 shares during the period. Claro Advisors LLC’s holdings in Cencora were worth $317,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other hedge funds also recently modified their holdings of the stock. Voleon Capital Management LP bought a new position in Cencora in the 1st quarter valued at about $3,111,000. Focus Partners Wealth grew its position in shares of Cencora by 25.8% in the first quarter. Focus Partners Wealth now owns 5,715 shares of the company’s stock valued at $1,589,000 after purchasing an additional 1,171 shares during the last quarter. Martin Capital Partners LLC increased its stake in shares of Cencora by 205.2% during the second quarter. Martin Capital Partners LLC now owns 3,784 shares of the company’s stock worth $1,135,000 after purchasing an additional 2,544 shares during the period. Fiduciary Alliance LLC acquired a new stake in Cencora during the 2nd quarter worth approximately $262,000. Finally, Ascent Group LLC boosted its stake in Cencora by 42.7% in the 1st quarter. Ascent Group LLC now owns 12,586 shares of the company’s stock valued at $3,500,000 after purchasing an additional 3,764 shares during the period. Institutional investors and hedge funds own 97.52% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have weighed in on COR shares. Weiss Ratings reiterated a “buy (b-)” rating on shares of Cencora in a research report on Thursday, October 30th. Wells Fargo & Company raised their price target on shares of Cencora from $337.00 to $354.00 and gave the stock an “overweight” rating in a research report on Wednesday, August 13th. Morgan Stanley set a $330.00 price objective on shares of Cencora and gave the company an “equal weight” rating in a report on Wednesday, July 16th. Wall Street Zen lowered shares of Cencora from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. Finally, Mizuho lifted their price target on shares of Cencora from $340.00 to $380.00 and gave the company an “outperform” rating in a research report on Thursday. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the stock. According to data from MarketBeat, Cencora has an average rating of “Moderate Buy” and an average target price of $348.00.

Insider Buying and Selling at Cencora

In other Cencora news, CEO Robert P. Mauch sold 5,097 shares of the business’s stock in a transaction dated Monday, October 20th. The stock was sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the completion of the transaction, the chief executive officer owned 37,940 shares of the company’s stock, valued at approximately $12,398,792. The trade was a 11.84% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, Chairman Steven H. Collis sold 31,350 shares of the stock in a transaction dated Tuesday, September 16th. The stock was sold at an average price of $289.86, for a total transaction of $9,087,111.00. Following the completion of the transaction, the chairman directly owned 305,913 shares of the company’s stock, valued at $88,671,942.18. This trade represents a 9.30% decrease in their position. The SEC filing for this sale provides additional information. Over the last 90 days, insiders have sold 41,544 shares of company stock valued at $12,230,941. 10.80% of the stock is owned by corporate insiders.

Cencora Price Performance

COR stock opened at $360.29 on Friday. The company’s 50-day moving average price is $312.89 and its two-hundred day moving average price is $298.79. Cencora, Inc. has a 12 month low of $223.92 and a 12 month high of $362.00. The company has a quick ratio of 0.53, a current ratio of 0.90 and a debt-to-equity ratio of 3.64. The firm has a market cap of $69.85 billion, a P/E ratio of 37.07, a P/E/G ratio of 1.56 and a beta of 0.63.

Cencora (NYSE:COR) last posted its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 earnings per share (EPS) for the quarter, topping the consensus estimate of $3.79 by $0.05. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business had revenue of $83.73 billion for the quarter, compared to analyst estimates of $83.36 billion. During the same quarter last year, the business posted $3.34 EPS. The firm’s revenue for the quarter was up 5.9% on a year-over-year basis. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. On average, analysts anticipate that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Stockholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. This is an increase from Cencora’s previous quarterly dividend of $0.55. The ex-dividend date of this dividend is Friday, November 14th. This represents a $2.40 dividend on an annualized basis and a dividend yield of 0.7%. Cencora’s payout ratio is presently 22.63%.

About Cencora

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.